沃森生物(300142.SZ):擬發行H股並申請在聯交所主板掛牌上市
格隆匯 10 月 20日丨沃森生物(300142.SZ)公佈,根據公司戰略規劃及業務發展需求,為進一步提高公司的資本實力和綜合競爭力,調整資本結構,利用境外資本市場融資能力,公司擬發行境外上市外資股(H股)並申請在香港聯交所主板掛牌上市。為完成此次發行上市,公司需根據法律、法規的規定轉為境外募集股份有限公司。
截至目前,公司正積極與相關中介機構就公司此次發行上市的相關工作進行商討,關於此次發行上市的具體細節尚未確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.